Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
ABC NewsRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit
Comments